Neuroscience Focus ERG specializes in early and late stage neuroscience drug development with in-patient and out-patient phase I-IV studies, providing opportunities to cross-sell specialized CNS trial design, patient recruitment, and centralized data services to pharma and CRO clients seeking neuroscience expertise.

Expansive Patient Network Access to a large mental health, neurological, sleep, pain, and other illness populations, plus healthy volunteers and 32 million potential subjects, enables targeted recruitment capabilities and scalable trial enrollment for diverse indications.

Integrated Site Network Ownership of 21 clinical sites plus affiliated locations across multiple regions, supported by centralized infrastructure in New Jersey, offers coordinated site management, faster startup, and potential to propose multi-site studies and faster patient access.

Data and Services Suite Offering centralized data services (ECG, PSG, EEG, qEEG, Actigraphy) and consulting in study design, feasibility, budgeting, and specialist Rater Training positions ERG as a one-stop partner for complex trials, appealing to sponsors seeking efficiency and quality.

Growth and Financing Signals Revenue range of 25 to 50 million and a private, independent structure suggest opportunities for strategic partnerships, co-development pilots, or accretive collaborations with mid-size sponsors seeking neuroscience-focused CRO capabilities.